BI 764532
Boehringer Ingelheim
[]
#asco23 bi 764532 still in escalation but this far, primary toxicity of note is cytokine release syndrome. crs in 59% of patients but almost all grade 1-2. still, this is one of the barriers to scalability for these agents, imo. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo